Welte, Thomas
Arnold, Frederic
Kappes, Julia
Seidl, Maximilian
Häffner, Karsten
Bergmann, Carsten
Walz, Gerd
Neumann-Haefelin, Elke http://orcid.org/0000-0001-5893-4293
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft
Article History
Received: 31 May 2017
Accepted: 18 December 2017
First Online: 12 January 2018
Ethics approval and consent to participate
: All patients gave written informed consent for eculizumab treatment. The study was approved by the Ethics Committee of the University Medical Center, Freiburg, Germany (reference number #400/16).
: Not applicable
: GW and CB have received honoraria for participating in Alexion Pharmaceuticals advisory board meetings. Alexion Pharmaceuticals was not involved in drafting, editing or publication of this study. CB is an employee of Bioscientia.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.